Noxopharm Limited   Report issue

For profit Phase 1 Phase 2
Founded: Gordon NSW Australia (2015)

Organization Overview

First Clinical Trial
2017
NCT02941523
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Noxopharm Limited

Active Ingredients

Drugs in Phase 2 Trials (3)

carboplatin (paraplatin) (1 trial)

idronoxil (5 trials)

phenoxodiol (1 trial)

Drugs in Phase 1 Trials (1)

doxorubicin (Doxil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 4